references
A DYNAMIC PORTFOLIO APPROACH
Diversified operational models to respond to evolving needs
C
reated in 2003, DNDi has always focused on developing adapted treatments for the most in need, endeavouring to fill R&D gaps whilst doing so. In 2015, DNDi released its Business Plan for the 2015-2023 period. The plan comprises a dynamic portfolio approach, adopted in order to address the evolving needs of public health importance and maintain DNDi’s commitment to meeting the objectives within the current portfolio of diseases (human African trypanosomiasis (HAT), leishmaniasis, Chagas disease, paediatric HIV, and filariasis), as well as to answer specific needs for new disease or research areas: mycetoma, hepatitis C, and antimicrobial resistance (AMR).
Because not every disease will require the same amount of R&D investment, a range of operating models – full portfolio, mini portfolio, and support model – has been defined to tailor DND i ’s involvement as appropriate and allow for responding to global health needs as they arise.
The Global Antibiotic Research and Development (GARD) Partnership
A joint initiative by WHO and DNDi, GARD’s vision is to work in cooperation with the public and private sectors, to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all, with a focus on global health needs.
OPERATING MODELS
Full portfolio
For HAT, Chagas disease, filariasis, and leishmaniasis
Budget of
Mini portfolio
For paediatric HIV, mycetoma, and hepatitis C
Budget of
Support
• • • • • Knowledge sharing Advocacy push Advisory role Build resource platform Incubator (see ‘GARD’ example above)
per portfolio
€100+ million
˜ €25 million per mini portfolio
Budget of up to million per support project
€1
• R&D Portfolio
3